Alkermes Plc (NASDAQ:ALKS) — Market Cap & Net Worth

$7.49 Billion USD · Rank #2709

Market Cap & Net Worth: Alkermes Plc (ALKS)

Alkermes Plc (NASDAQ:ALKS) has a market capitalization of $7.49 Billion ($7.49 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2709 globally and #971 in its home market, demonstrating a -7.51% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alkermes Plc's stock price $48.99 by its total outstanding shares 166675807 (166.68 Million). See ALKS capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.

Alkermes Plc Market Cap History: 2015 to 2026

Alkermes Plc's market capitalization history from 2015 to 2026. Data shows change from $13.23 Billion to $8.17 Billion (-2.21% CAGR).

Index Memberships

Alkermes Plc is a constituent of 7 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
ARCA Biotechnology BTK	$935.64 Billion	0.80%	#23 of 30
Dow Jones Biotechnology DJUSBT	$1.09 Trillion	0.69%	#17 of 39
ARCA Pharmaceutical DRG	$3.28 Trillion	0.23%	#17 of 24
NASDAQ Health Care IXHC	$2.46 Trillion	0.30%	#60 of 976
NASDAQ Composite IXIC	$40.26 Trillion	0.02%	#308 of 3165
NASDAQ Biotechnology NBI	$1.72 Trillion	0.43%	#40 of 263
S&P Small-Cap 600 Index SML	$1.60 Trillion	0.38%	#28 of 602

Weight: Alkermes Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Alkermes Plc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Alkermes Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

3.16x

Alkermes Plc's market cap is 3.16 times its annual revenue

Industry average: 0.63x Higher than industry average

Latest Price to Earnings (P/E) Ratio

19.30x

Alkermes Plc's market cap is 19.30 times its annual earnings

Industry average: 4.55x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$9.26 Billion	$745.69 Million	-$208.44 Million	12.42x	N/A
2017	$9.12 Billion	$903.37 Million	-$157.94 Million	10.10x	N/A
2018	$4.92 Billion	$1.09 Billion	-$139.31 Million	4.49x	N/A
2019	$3.40 Billion	$1.17 Billion	-$196.62 Million	2.90x	N/A
2020	$3.33 Billion	$1.04 Billion	-$110.86 Million	3.20x	N/A
2021	$3.88 Billion	$1.17 Billion	-$48.17 Million	3.30x	N/A
2022	$4.36 Billion	$1.11 Billion	-$158.27 Million	3.92x	N/A
2023	$4.62 Billion	$1.66 Billion	$355.76 Million	2.78x	13.00x
2024	$4.79 Billion	$1.56 Billion	$367.07 Million	3.08x	13.06x
2025	$4.66 Billion	$1.48 Billion	$241.66 Million	3.16x	19.30x

Competitor Companies of ALKS by Market Capitalization

Companies near Alkermes Plc in the global market cap rankings as of August 1, 2026.

Key companies related to Alkermes Plc by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#503	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#528	Jiangsu Hengrui Medicine Co Ltd	SHG:600276	$50.48 Billion	CN¥54.08
#550	GALDERMA GROUP AG	NYSE:GALDY	$48.78 Billion	$43.60
#619	Takeda Pharmaceutical Company Limited	F:TKDA	$43.60 Billion	€15.50

Alkermes Plc Historical Marketcap From 2015 to 2026

Between 2015 and today, Alkermes Plc's market cap moved from $13.23 Billion to $ 8.17 Billion, with a yearly change of -2.21%.

Year	Market Cap	Change (%)
2026	$8.17 Billion	+75.09%
2025	$4.66 Billion	-2.71%
2024	$4.79 Billion	+3.68%
2023	$4.62 Billion	+6.16%
2022	$4.36 Billion	+12.34%
2021	$3.88 Billion	+16.59%
2020	$3.33 Billion	-2.21%
2019	$3.40 Billion	-30.87%
2018	$4.92 Billion	-46.08%
2017	$9.12 Billion	-1.53%
2016	$9.26 Billion	-29.98%
2015	$13.23 Billion	--

End of Day Market Cap According to Different Sources

On Aug 1st, 2026 the market cap of Alkermes Plc was reported to be:

Source	Market Cap
Yahoo Finance	$7.49 Billion USD
MoneyControl	$7.49 Billion USD
MarketWatch	$7.49 Billion USD
marketcap.company	$7.49 Billion USD
Reuters	$7.49 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Alkermes Plc

NASDAQ:ALKS USA Drug Manufacturers - Specialty & Generic

Market Cap

$8.17 Billion

Market Cap Rank

#2709 Global

#971 in USA

Share Price

$48.99

Change (1 day)

-2.08%

52-Week Range

$26.52 - $55.22

All Time High

$80.14